HEMO ORGANIC LIMITED
CIN - L24231GJ1992PLC018224
Address: Shop 1 to 3, First floor, Piyu Apartment Opp Electricity Sub Station & Mahesh Nagar, Nr. Radhika Chambers & Jay Amarnath Society, Nikol Gam Road, Uttamnagar, Ahmedabad, Gujarat, India – 382 350
Email ID: hemoorganic@gmail.com **Website**: www.hemoorganic.co **Ph. No.** 8238557874

Date: 15th July, 2026

To,
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai – 400 001

Dear Sir/Ma'am,

Sub: Outcome of Board Meeting held today i.e., Wednesday, 15th July, 2026

Ref: Scrip Code: 524590 | Symbol: HEMORGANIC | ISIN: INE422G01015

The Board of Directors ("the Board") at its meeting held on 15th July, 2026 which commenced at 04:00 p.m. and concluded at 05:15 p.m., has approved and taken on record inter alia:

a) The Un-audited Financial Results of the Company for the quarter ended as on 30th June, 2026 prepared in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015 along with Limited Review Report thereon.

b) To transact other businesses as per agenda being circulated.

You are requested to take note of the above.

Thanking You,
Yours faithfully,

For, Hemo Organic Limited

VISHWAMBAR KAMESHWAR SINGH
Digitally signed by VISHWAMBAR KAMESHWAR SINGH
Date: 2026.07.15 17:21:13 +05'30'

Vishwambar Kameshwar Singh
Managing Director
DIN: 09822587

MAAK & ASSOCIATES
Chartered Accountants

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS HEMO ORGANIC LIMITED PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 FOR THE PERIOD ENDED 30th JUNE, 2026

To,

The Board of Directors,
HEMO ORGANIC LIMITED

We have reviewed the accompanying statement of unaudited financial results of M/s HEMO ORGANIC LIMITED for the quarter ended 30th June,2026, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FCA/62/2016 dated July 5, 2016.

This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard (Ind AS) 34 on 'Interim Financial Reporting', prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, except as specified in Qualified Opinion para, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

MAAK & ASSOCIATES
FRN: 135024W
AHMEDABAD
CHARTERED ACCOUNTANTS

Qualified Opinion:

1. We have not been provided with the balance confirmation or any other details for the trade receivable & trade payable in the books of accounts & in the absence of the same we are unable to confirm the balance and nature of the transaction.

Date: 15/07/2026
Place: Ahmedabad
UDIN: 26139533JUQSJQ3583

For, M A A K & Associates
(Chartered Accountants)
F.R.N.:135024W

MAAK & ASSOCIATES
FRN: 135024W
AHMEDABAD
CHARTERED ACCOUNTANTS

CA Kenan Satyawadi
(Partner)
Mem.No.:139533

HEMO ORGANIC LIMITED

CIN: L24231GJ1992PLC018224

Registered Office: Shop 1-3, 1 Floor, Piyu apartment, Opp. Electricity sub station, Jay amarnath society, Nikol, Ahmedabad, Gujarat, India, 382350

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED ON 30th June, 2026

(Rs. In lakh)

	Particulars	Quarter ended on			Year Ended on
		30-06-2026	31-03-2026	30-06-2025	31-03-2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	**Revenue from operations**	-	92.70	0.19	92.90
2	**Other income**	-	-	-	0.20
3	**Total Income (1+2)**	-	**92.70**	**0.19**	**93.10**
4	**Expenses**				
	a. Purchases	-	(29.01)	31.14	2.13
	b. Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	121.79	(31.00)	90.80
	c. Employee benefits expense	1.36	1.10	2.85	6.53
	d. Finance costs	-	-	-	-
	e. Depreciation & amortisation expense	0.01	0.01	0.01	0.06
	f. Other expenses	6.05	28.50	8.64	43.41
	Total Expenses	**7.42**	**122.39**	**11.64**	**142.93**
5	Profit / (Loss) before exceptional items and tax (3-4)	**(7.42)**	**(29.69)**	**(11.45)**	**(49.83)**
6	Exceptional items	-	-	-	-
7	Profit / (Loss) before tax (5+6)	**(7.42)**	**(29.69)**	**(11.45)**	**(49.83)**
8	Tax expense:	-	-	-	-
	Current tax	-	-	-	-
	Deferred tax	-	20.83	(2.88)	27.93
	Tax relating to earlier period	-	0.05	-	0.05
	Total tax expense	-	**20.88**	**(2.88)**	**27.98**
9	Profit (Loss) for the period from continuing operations (7-8)	**(7.42)**	**(50.57)**	**(8.57)**	**(77.81)**
10	Profit/(loss) from discontinuing operations before Tax	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-
12	Profit/(loss) from Discontinuing operations (after tax) (10-11)	-	-	-	-
13	Profit / (Loss) for the period (9+12)	**(7.42)**	**(50.57)**	**(8.57)**	**(77.81)**
14	**Other Comprehensive Income**				
	Items that will not be reclassified subsequently to profit or loss	-	-	-	-
	Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	Items that will be reclassified subsequently to profit or loss	-	-	-	-
	Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	Other Comprehensive Income, net of tax	-	-	-	-
15	**Total Comprehensive Income for the period (13+14)**	**(7.42)**	**(50.57)**	**(8.57)**	**(77.81)**
16	Paid up equity share capital (Face value of Rs. 10 each)	346.59	346.59	346.59	346.59
17	Earnings Per equity share (Face value of Rs. 10 each)				
	1) Basic	(0.21)	(1.46)	(0.25)	(2.24)
	2) Diluted	(0.21)	(1.46)	(0.25)	(2.24)

Place: Ahmedabad
Date : 15/07/2026

HEMO ORGANIC LIMITED

By order of the Board
Hemo Organic Limited

Vishwambhar Singh
Managing Director
DIN: 09822587

Notes:

1 The above standalone financial results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meeting held on 15th July, 2026.

2 The financial results of the company have been prepared in accordance with Indian Accounting Standards prescribed under section 133 of the companies Act, 2013 read with relevant rules there under and in terms with regulation 33 of SEBI (Listing Obligation and Disclosures Requirements) regulations 2015 and SEBI circular dated 5th July 2016.

3 The statutory Auditors of the company have carried out a "Limited Review" of the above result as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The IND AS compliant corresponding figures of the previous year have not been subject to review. However the company's management has excercised necessary due diligence to ensure that such financial results provide true and fair view.

4 Earning per share for the quarter and year ended has been calculated as per weighted average formula and diluted Earning per share has been calculated considering proposed issue of equity shares on account of conversion of convertible securities if any.

5 Previous period figures have been reclassified / regrouped wherever considered necessary to confirm to the current period figures.

Date : 15/07/2026
Place: Ahmedabad

By order of the Board
Hemo Organic Limited

HEMO ORGANIC LIMITED

Vishwambhar Singh
Managing Director
DIN: 09822587